Tandem Diabetes Care (TNDM) Corporate presentation summary

Market opportunity and customer base

• Serves a large, underpenetrated global market with less than 40% of type 1 diabetes patients in the U.S. and less than 20% in other served countries using insulin pumps.

• Approximately 480,000 in-warranty customers across 25 countries as of December 2024.

• Headquartered in San Diego with about 2,600 employees worldwide.

Product portfolio and technology

• Offers two pump platforms: t:slim X2 and Tandem Mobi, both featuring Control-IQ+ technology and cleared for type 1 and type 2 diabetes.

• Pumps integrate with multiple CGM sensors, including Dexcom G6/G7 and Abbott FreeStyle Libre 2 Plus, with Libre 3 Plus integration planned for 2025.

• Tandem Mobi is 55% smaller than other pumps, offers on-body wear, and can be controlled via iPhone.

• t:slim X2 is the first U.S. pump to integrate with three CGM sensors and supports both iPhone and Android bolus delivery.

Advanced algorithm and clinical outcomes

• Control-IQ+ technology automates insulin delivery, predicts and helps prevent highs and lows, and is FDA cleared for type 1 (ages 2+) and type 2 (ages 18+).

• Over 440,000 pump users and 250 million+ patient days of Control-IQ technology use.

• Demonstrates best-in-class outcomes with fewer adverse events and sustained improvements.